ApoE4.Info and the ApoE4 Alzheimer's Alliance, two Washington-based nonprofit organizations, announced an ApoE4 partnership on March 16, 2026, to coordinate advocacy, education, and policy efforts on behalf of individuals carrying the ε4 allele of the APOE gene (announcement). The collaboration does not involve a drug, biologic, or technology platform. Neither organization is a pharmaceutical or biotechnology company, and no licensing terms, financial consideration, or intellectual property exchange were described.
The partnership combines ApoE4.Info's global education and community network with the ApoE4 Alzheimer's Alliance's policy and legislative advocacy infrastructure. ApoE4.Info is a 501(c)(3) nonprofit founded in 2013 that provides evidence-based resources and peer support to APOE4 carriers. The ApoE4 Alzheimer's Alliance, known as A3, is a 501(c)(4) organization focused on federal research agendas, clinical trial design standards, and national Alzheimer's strategy.
No financial terms were disclosed. The announcement contained no upfront payments, milestone structures, royalties, equity components, or other deal economics. The arrangement is a mission-aligned advocacy collaboration rather than a commercial transaction. The "Licensing" classification applied by the wire service does not reflect the substance of the announcement.
Deal context
APOE4 carriers represent up to 65% of people diagnosed with Alzheimer's disease, according to the organizations. The APOE4 variant is the strongest known genetic risk factor for late-onset Alzheimer's. Carriers exhibit altered lipid metabolism, increased neuroinflammation, vascular vulnerability, and differential responses to therapies compared with non-carriers. Despite these differences, carriers are frequently grouped with non-carriers in clinical trials, treatment guidelines, and prevention messaging.
The partnership's stated objectives include advocating for routine APOE stratification in clinical trials, expanding research into genotype-informed prevention and treatment strategies, and shaping public policies that reflect the needs of APOE4 carriers. Julie Gregory, president of ApoE4.Info, stated that genotype-specific risk, progression patterns, and treatment responses should be central to research design and policy decisions. William Burke, executive director of A3, described the effort as precision advocacy Alzheimer's stakeholders should incorporate into federal regulatory and industry frameworks.
Several drug development programs are currently investigating therapies in APOE4-defined patient populations, though none are assets of either organization. These include:
- ALZ-801 — Alzheon Inc. — Phase 3 in early Alzheimer's disease in APOE4/4 homozygotes (NCT04770220)
- Lecanemab — Eisai Inc. — approved by the US FDA for early Alzheimer's disease, with ongoing extension studies (NCT03887455)
- T3D-959 — T3D Therapeutics — Phase 2 completed in mild-to-moderate Alzheimer's disease (NCT04251182)
The organizations' advocacy for APOE stratification in trial design intersects with an ongoing debate in Alzheimer's drug development. Lecanemab's clinical program showed differential safety signals in APOE4 homozygotes, including higher rates of amyloid-related imaging abnormalities. Alzheon's ALZ-801 program is designed exclusively for APOE4/4 carriers, representing one of the few genotype-restricted Alzheimer's trials in late-stage development.
The partnership does not involve co-development of any therapeutic, diagnostic, or technology platform. Its scope is limited to advocacy, education, and policy influence. The two organizations plan to amplify the lived experiences of carriers and their families to help shape future Alzheimer's care standards. They invited researchers, clinicians, industry leaders, and policymakers to support genotype-informed approaches to the disease.
Spot something wrong? Report an issue with this article